2080367-38-8

Basic information

• Product Name: 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate
• CAS NO: 2080367-38-8
• Molecular Weight: 348.442
• Mol File: 2080367-38-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate(2080367-38-8)
• EPA Substance Registry System: 4-benzyl 1-(tert-butyl) (2R,6S)-2,6-dimethylpiperazine-1,4-dicarboxylate(2080367-38-8)

Safety Data

• Hazardous Substances Data: 2080367-38-8(Hazardous Substances Data)

Upstream product

• 501-53-1 benzyl chloroformate 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 623585-97-7 benzyl (3S,5R)-3,5-dimethylpiperazine-1-carboxylate 
• 108-49-6 3,5-dimethylpiperazine 
• 885278-83-1 benzyl 3,5-dimethylpiperazine-1-carboxylate 

Relevant articles and documents

Design, synthesis and SAR of antitubercular benzylpiperazine ureas

Abstract: N-furfuryl piperazine ureas disclosed by scientists at GSK Tres Cantos were chosen as antimycobacterial hits from a phenotypic whole-cell screen. Bioisosteric replacement of the furan ring in the GSK Tres Cantos molecules with a phenyl ring led to molecule (I) with an MIC of 1?μM against Mtb H37Rv, low cellular toxicity (HepG2 IC50 ~ 80?μM), good DMPK properties and specificity for Mtb. With the aim of delineating the SAR associated with (I), fifty-five analogs were synthesized and screened against Mtb. The SAR suggests that the piperazine ring, benzyl urea and piperonyl moieties are essential signatures of this series. Active compounds in this series are metabolically stable, have low cellular toxicity and are valuable leads for optimization. Molecular docking suggests these molecules occupy the Q0 site of QcrB like Q203. Graphic Abstract: Bioisosteric replacement of N-furfuryl piperazine-1-carboxamides yielded molecule (I) a novel lead with satisfactory PD, metabolism, and toxicity profiles.[Figure not available: see fulltext.]

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.